Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.04
  • Today's Change-0.23 / -1.26%
  • Shares traded10.30m
  • 1 Year change-18.92%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.

  • Revenue in CNY (TTM)264.22bn
  • Net income in CNY3.79bn
  • Incorporated1994
  • Employees48.16k
  • Location
    Shanghai Pharmaceuticals Holding Co LtdShanghai Pharmaceutical MansionNo.200 Taicang RoadSHANGHAI 200020ChinaCHN
  • Phone+86 2 163730908
  • Fax+86 2 163289333
  • Websitehttps://www.sphchina.com/index/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Meheco Group Co Ltd35.07bn924.87m16.60bn8.39k17.951.42--0.47350.61830.618323.447.830.92244.582.284,180,309.002.963.406.727.7611.2214.153.212.931.228.890.33528.223.284.6042.45-7.466.72-1.02
China National Medicines Corp Ltd50.59bn2.19bn26.61bn3.14k12.151.64--0.5262.902.9067.0521.511.6111.216.5816,122,340.007.577.3214.4115.037.638.154.704.311.77--0.127130.049.235.119.268.851.8416.38
Jointown Pharmaceutical Group Co Ltd148.52bn2.17bn30.76bn30.10k14.391.25--0.20710.54690.546937.576.281.538.053.964,934,201.002.313.017.859.727.688.241.501.980.97823.500.567334.736.9211.504.8814.16-10.3939.14
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd76.83bn4.11bn50.18bn28.05k12.811.43--0.6532.522.5247.2522.681.016.704.702,739,343.005.675.9010.5612.4018.0718.705.635.561.35--0.313230.026.6812.322.253.3427.7512.05
Shanghai Pharmaceuticals Holding Co Ltd264.22bn3.79bn61.20bn48.16k17.770.9657--0.23161.031.0371.5718.921.257.103.385,485,870.002.403.536.339.3411.3413.211.922.661.077.550.40332.8912.2110.35-32.92-0.58968.860.00
Zhangzhou Pientzhng Phrmctcl Co Ltd10.60bn3.00bn143.28bn2.79k47.7310.00--13.524.984.9817.5723.760.63541.7413.243,800,528.0018.3018.8222.6123.9145.7746.5528.8127.984.02--0.089836.4915.6916.1113.1519.6013.8331.06
Data as of May 22 2024. Currency figures normalised to Shanghai Pharmaceuticals Holding Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.76%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 31 Dec 202321.53m1.12%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 202314.01m0.73%
Orient Securities Asset Management Co. Ltd.as of 30 Jun 202312.45m0.65%
Yinhua Fund Management Co., Ltd.as of 30 Jun 202311.60m0.60%
China Universal Asset Management Co., Ltd.as of 31 Dec 202311.39m0.59%
China Southern Asset Management Co., Ltd.as of 31 Dec 20238.80m0.46%
GF Fund Management Co., Ltd.as of 31 Dec 20238.44m0.44%
Norges Bank Investment Managementas of 31 Dec 20238.40m0.44%
Lion Fund Management Co., Ltd.as of 31 Dec 20237.55m0.39%
The Vanguard Group, Inc.as of 09 May 20246.84m0.36%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.